The Cognitive Ageing Nutrition and Neurogenesis (CANN) trial: investigating the effects of a flavonoid/fatty acid supplement on cognitive functio

Not Applicable

Completed

• Conditions: Mild Cognitive Impairment; Subjective Memory Impairment; Alternative and Complementary Medicine - Other alternative and complementary medicine; Neurological - Other neurological disorders

• Registration Number: ACTRN12615001053516
• Lead Sponsor: Swinburne Univeristy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

For main study:
Male and female, aged 55 years and over
Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression
Willing and able to provide written informed consent.
Understands and is willing and able to comply with all study procedures.
Fluent in written and spoken English.
In good general health including blood biochemical, haematological and urinalysis within the normal range at
screening (as judged by the clinical advisor)
Normal, or corrected to normal vision and hearing
Right handed, for MRI
Stable use of any prescribed medication for at least four weeks

For healthy controls sub-study:
The same inclusion criteria apply except that participants must not have MCI or SMI

Exclusion Criteria

Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder
Parent or sibling who developed premature dementia <60y (suggestive of a familial monogenic form of cognitive decline)
Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness > 24 hours
History of alcohol or drug dependency within the last 2 years
Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
Carotid stents or severe stenosis
Known allergy to fish or any other component in the intervention supplements
Existing medical conditions likely to affect the study measures (as judged by clinical adviser)
Uncontrolled hypertension (Systolic Blood Pressure (SBP) >140mmHg, Diastolic Blood Pressure (DBP) >90mmHg)
BMI >40kg/m2

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of false positive responses during the picture recognition task of the CDR Computerized Cognitive Assessment System. This is a measure of cognitive function.[at baseline and at 12 months post commencement of intervention]